Mersana Therapeutics Inc (MRSN) Gets a Buy Rating from Robert W. Baird


In a report released yesterday, Michael Ulz from Robert W. Baird reiterated a Buy rating on Mersana Therapeutics Inc (NASDAQ: MRSN), with a price target of $20. The company’s shares opened today at $12.75.

According to TipRanks.com, Ulz is a 3-star analyst with an average return of 2.9% and a 47.9% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Karyopharm Therapeutics, and Jounce Therapeutics Inc.

Currently, the analyst consensus on Mersana Therapeutics Inc is a Strong Buy with an average price target of $18, representing a 41.2% upside. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $23.96 and a one-year low of $8.76. Currently, Mersana Therapeutics Inc has an average volume of 176.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts